采访/陈汉 编辑/陈洁 后制/李勇
Real Name Report On Food and Drug Administration Director
A Hunan Provincial Commission for Discipline Inspection
official recently issued a report online regarding former
Director of the State Food and Drug Administration,
Shao Mingli, using his real name.
Shao was said to have played a key role in changing
the name of a famous Chinese herb.
He served as a representative for the herb that replaced
a well-known herb, causing huge economic loss of tens
of millions of growers.
Analysts point out that Shao Mingli has been involved
in the CCP's organ harvesting.
His umbrella of protection has always helped to him avoid
charges, but the informants are always persecuted.
On Aug. 12, deputy director of the Prevention of Corruption
of Hunan Provincial Commission for Discipline Inspection,
Lu Qun, issued 13 blog statements regarding Shao Mingli
with his real name.
He indicated that Shao changed the name of a southern
Chinese herb, Jin-yin-hua, to San-yin-hua.
Shao also specified the herb to be Jin-yin-hua
in his hometown in Shandong.
Shao Mingli is a Shandong native.
He held various posts at the Ministry of Health
and the state Food and Drug Administration.
In June 2005 he was promoted to Director of the FDA
and in March 2008 he served as Deputy Minister of Health.
In Feb. 2012, he was dismissed from the Ministery of Health
and the FDA, but transferred to the State Pharmacopoeia
Commission as Deputy Chairman.
Lu Qun stated in the blog that after the name change,
the price of good quality Southern Jin-yin-hua plummeted.
Northern traders took the opportunity to acquire the herb
at low cost and sell at high prices as the northern herb.
Tens of millions of southern growers were left to endure
a tremendous economic loss.
Mr. Xia, a retiree from a Hunan drug company:
"Since the herb was renamed in 2005, doctors,
society and the market do not recognize the new name.
Jin-yin-hua was left with no market."
Lu Qun wrote that in order to bring down the Southern
Jin-yin-hua industry, Shandong's industry spent huge sums
on public relations to change the name through
the national pharmacopoeia.
They then spread rumors to slander the southern Jin-yin-hua
as causing side effects.
A Chongqing public relations company admitted to accepting
a 1.3 million yuan PR fee to publicize the rumors.
The amount of bribery FDA officials have received
Lu Qun indicates that he will expose the corrupt FDA
with solid evidence.
Lu Qun: "The State FDA baselessly renamed the southern
Jin-yin-hua as San-yin-hua.
The publicized responses do not sustain.
I will refute them quickly and prove them lying.
In fact, the entire FDA at local levels has endorsed for local
interest groups and have been controlled by interest groups.
I will show all the evidence."
Lu Qun's blogs have sparked heated discussion
Some demanded public investigation.
Others worried for Lu Qun's safety.
The Epoch Times columnist Zhou Xiaohui indicates that as
early as when former Director of FDA Zheng Xiaoyu
was executed for taking bribes in 2007, Shao Mingli had been
reported by a China Consumer News journalist, Gao Chun.
Gao Chun reported that Zheng Xiaoyu's death has masked
Shao Mingli's crimes.
Between 1995 and 1998, no one questioned how Director
of FDA Shao Minli approved the sale of the drug.
Mr. Zou, Xi'an pharmaceutical salesman (voice modified):
"The high State FDA officials abused the approval process.
For instance, the manufacturers delivered the drugs
The process of getting a license should be very strict.
But, they would just do it randomly, a few in a day
or sometimes one every few days.
It is very common."
Zhou Xiaohui indicates that a series of fatalities and
disabilities caused by food and drug have occurred during
Shao Mingli's power, but he often escaped being
Who is covering for Shao Mingli while Gao Chun has been
repeatedly persecuted for his persistent reports on Shao?
Zhou Xiaohui reveals that Shao Mingli has close ties
to Novartis Pharmaceuticals.
He also had interactions with the Swiss pharmaceutical
The immunosuppressive agents produced by these two
companies are widely used by China's kidney transplant patients.
Between January 2005 and June 2006, Novartis conducted
a kidney test on 300 people.
The test was done in Shanghai First People's Hospital,
a hospital alleged to be engaged in organ harvesting
from living Falun Gong practitioners.
Zhou Xiaohui points out that rapid development of Novartis
and Roche in China is inseparable from the CCP crime's
of organ harvesting from living Falun Gong practitioners.
Shao Mingli, responsible for the drug approval,
cannot escape from his sins.
Interview/ChenHan Edit/ChenJie Post-Production/LiYong